Tomas Mustelin, MD, PhD
Tomas Mustelin has been a full professor since 1999 (at 38 years of age) and has published 250 papers. He has over 10 years of industry experience as vice president at Amgen, MedImmune/AstraZeneca and Gilead, where he led research and the preclinical development of novel therapeutics in autoimmune, inflammatory/respiratory diseases and immune-oncology. During that time, he served as the site head for Amgen’s Washington site and head of research at MedImmune. He is now the Herndon and Esther Maury Endowed Professor in Rheumatoid Arthritis, professor of medicine, and interim chief of the Division of Rheumatology at the University of Washington, Seattle. His current research is focused on deciphering the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Tomas received his MD and PhD degrees from the University of Helsinki, Finland, held a post-doctoral research position at Scripps Clinic in La Jolla, California, and has been a licensed physician in the EU since 1991.